Identification of tumor affine peptides in head and neck tumors by display techniques

本研究旨在利用高通量技术鉴定针对头颈部肿瘤的肿瘤仿射肽。这些分子将在放射性同位素或荧光染料标记后用于成像，或在α或β发射同位素标记后用于治疗或与化疗药物偶联。对头颈癌具有亲和力的新配体的鉴定是基于肽库和噬菌体或核糖体展示以及肿瘤细胞膜的差异表达部分来完成的。这些肿瘤细胞膜将使用新的蛋白质组学技术分离。这种蛋白质组学技术也将在后期阶段用于鉴定结合肽的目标结构。在新发现的头颈癌靶结构的情况下，计划在更大的头颈肿瘤人群中对其表达进行表征。配体的临床前评估是在细胞系、组织切片、生物分布和荷瘤小鼠的成像实验中进行的。

This proposal aims at identifying tumor affine peptides against head and neck tumors using high throughput techniques. These molecules will be used for imaging after labeling with radioisotopes or fluorescence dyes or for therapy after labeling with alpha or beta emitting isotopes or coupling to chemotherapeutic drugs. The identification of new ligands with affinity towards head and neck cancer is done with peptide libraries and based on phage or ribosome display and differentially expressed parts of tumor cell membranes. These tumor cell membranes will be isolated using a new proteomics technology. This proteomics technology will also be used at later stages for the identification of the target structures for the binding peptides. In case of newly identified target structures for head and neck cancer a characterization of their expression in a larger population of head and neck tumors is planned. The preclinical evaluation of the ligands is performed in binding studies in cell lines, tissues slices, biodistribution and imaging experiments in tumor bearing mice.